

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES


Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



(19)

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 0 747 052 A2

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
11.12.1996 Bulletin 1996/50

(51) Int. Cl.⁶: **A61K 31/445**, **A61K 31/40**,
A61K 31/55

(21) Application number: 96303877.3

(22) Date of filing: 30.05.1996

(84) Designated Contracting States:
AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL
PT SE

(30) Priority: 07.06.1995 US 474936

(71) Applicant: **ELI LILLY AND COMPANY**
Indianapolis, Indiana 46285 (US)


(72) Inventors:
• **Berg, David Thompson**
Beech Grove, Indiana 46107 (US)

• **Calnek, David Scott**
Indianapolis, Indiana 46250 (US)
• **Grinnell, Brian William**
Indianapolis, Indiana 46220 (US)

(74) Representative: **Hudson, Christopher Mark et al**
Lilly Industries Limited
European Patent Operations
Erl Wood Manor
Windlesham Surrey GU20 6PH (GB)


(54) **Methods of modulating NF-KB transcription factor**

(57) A method of modulating NF-kB transcription factor comprising administering to a human in need thereof an effective amount of a compound having the formula



(I)

wherein R¹ and R³ are independently hydrogen, -CH₃,



wherein Ar is optionally substituted phenyl;

R² is selected from the group consisting of pyrrolidine, hexamethyleneamino, and piperidino; or a pharmaceutically

(Cont. next page)

EP 0 747 052 A2

acceptable salt of solvate thereof.

Description

Background of the Invention

The control of all biological processes results from a balance between various positive and negative-acting factors which interact with DNA regulatory elements and with each other. These protein factors play a critical role in controlling the expression of proteins, and thus are critical to both normal and pathological processes. Understanding these protein factors and how they modulate gene expression is key to strategies for the development of agents to control disease initiation and progression.


A number of these important trans-acting regulatory proteins have been described in the literature and have been demonstrated to play a role in pathological processes. One such factor is NF- κ B, a member of the Rel family of eukaryotic transcription factors. The Rel family of proteins controls a wide variety of cellular responses. For example, they are key regulatory molecules for signal-responsive induction of gene expression, host-defensive responses, and growth responses. The ability to specifically modulate the binding of NF- κ B and other members of the Rel family would be useful for the treatment of a wide variety of conditions ranging from septic shock, graft vs host reactions, acute inflammatory conditions, systemic inflammatory responses, acute phase responses, vascular coagulation, ischemic reperfusion injury, atherosclerosis, HIV infection and cancer.

Another transcription factor of importance is BEF-1, a member of the NF-1 family of transcriptional regulators. BEF-1 was first identified as a transcriptional repressor within the enhancer of human BK virus. The binding site for this ubiquitous transcription factor is present in the regulatory regions of a number of human genes. For example, BEF-1 has been shown to control the expression of human apolipoprotein E, a major constituent of plasma lipoprotein that functions in lipid transport and redistribution (reverse cholesterol transport). ApoE also probably plays an important role in inhibiting the development and /or progression of atherosclerosis. Both the level and binding activity of BEF-1 have been shown to be regulated via intracellular signaling, as demonstrated by effects mediated through the viral oncogene E1a, cytokines and also through tyrosine phosphorylation.


We have found that BEF-1 binding sites can overlap with NF- κ B binding sites (e.g., vascular adhesion molecule-1 : VCAM-1). Conversely, BEF-1 binding sites such as in the apoE promoter can bind Rel proteins. Thus, both BEF-1 and NF- κ B may compete for binding at the same site. Furthermore, compounds that modulate the levels of BEF-1 activity may be effective not only in modulating genes controlled by BEF-1, but those controlled by NF- κ B as well.

SUMMARY OF THE INVENTION

This invention provides methods for modulating NF- κ B transcription factor comprising administering to a human in need thereof an effective amount of a compound of formula I



wherein R^1 and R^3 are independently hydrogen, $-CH_3$;



wherein Ar is optionally substituted phenyl;

R² is selected from the group consisting of pyrrolidino, hexamethyleneimino, and piperidino; and pharmaceutically acceptable salts and solvates thereof.

DETAILED DESCRIPTION OF THE INVENTION

The current invention concerns the discovery that a select group of 2-phenyl-3-arylbenzothiophenes (benzothiophenes), those of formula I, are useful for modulating NF-κB transcription factor.

The methods of use provided by this invention are practiced by administering to a human in need thereof a dose of a compound of formula I or a pharmaceutically acceptable salt or solvate thereof, that is effective to modulate NF-κB transcription factor. As such, the present method includes both medical therapeutic and/or prophylactic administration, as appropriate.

Raloxifene, a compound of this invention wherein it is the hydrochloride salt of a compound of formula I, R¹ and R³ are hydrogen and R² is 1-piperidinyl, is a nuclear regulatory molecule. Raloxifene has been shown to bind to the estrogen receptor and was originally thought to be a molecule whose function and pharmacology was that of an anti-estrogen in that it blocked the ability of estrogen to activate uterine tissue and estrogen dependent breast cancers. Indeed, raloxifene does block the action of estrogen in some cells; however in other cell types, raloxifene activates the same genes as estrogen does and displays the same pharmacology, e.g., osteoporosis, hyperlipidemia. As a result, raloxifene has been referred to as an anti-estrogen with mixed agonist-antagonist properties. The unique profile which raloxifene displays and differs from that of estrogen is now thought to be due to the unique activation and/or suppression of various gene functions by the raloxifene-estrogen receptor complex as opposed to the activation and/or suppression of genes by the estrogen-estrogen receptor complex. Therefore, although raloxifene and estrogen utilize and compete for the same receptor, the pharmacological outcome from gene regulation of the two is not easily predicted and is unique to each.

Generally, the compound is formulated with common excipients, diluents or carriers, and compressed into tablets, or formulated as elixirs or solutions for convenient oral administration, or administered by the intramuscular or intravenous routes. The compounds can be administered transdermally, and may be formulated as sustained release dosage forms and the like.

The compounds used in the methods of the current invention can be made according to established procedures, such as those detailed in U.S. Patent Nos. 4,133,814, 4,418,068, and 4,380,635 all of which are incorporated by reference herein. In general, the process starts with a benzo[b]thiophene having a 6-hydroxyl group and a 2-(4-hydroxyphenyl) group. The starting compound is protected, acylated, and deprotected to form the formula I compounds. Examples of the preparation of such compounds are provided in the U.S. patents discussed above. Optionally substituted phenyl includes phenyl and phenyl substituted once or twice with C₁-C₆ alkyl, C₁-C₄ alkoxy, hydroxy, nitro, chloro, fluoro, or tri(chloro or fluoro)methyl.

The compounds used in the methods of this invention form pharmaceutically acceptable acid and base addition salts with a wide variety of organic and inorganic acids and bases and include the physiologically acceptable salts which are often used in pharmaceutical chemistry. Such salts are also part of this invention. Typical inorganic acids used to form such salts include hydrochloric, hydrobromic, hydroiodic, nitric, sulfuric, phosphoric, hypophosphoric and the like. Salts derived from organic acids, such as aliphatic mono and dicarboxylic acids, phenyl substituted alkanic acids, hydroxyalkanoic and hydroxyalkandioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, may also be used. Such pharmaceutically acceptable salts thus include acetate, phenylacetate, trifluoroacetate, acrylate, ascorbate, benzoate, chlorobenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, methylbenzoate, o-acetoxybenzoate, naphthalene-2-benzoate, bromide, isobutyrate, phenylbutyrate, β-hydroxybutyrate, butyne-1,4-dioate, hexyne-1,4-dioate, caprate, caprylate, chloride, cinnamate, citrate, formate, fumarate, glycollate, heptanoate, hippurate, lactate, malate, maleate, hydroxymaleate, malonate, mandelate, mesylate, nicotinate, isonicotinate, nitrate, oxalate, phthalate, teraphthalate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, propionate, propionate, phenylpropionate, salicylate, sebacate, succinate, suberate, sulfate, bisulfate, pyrosulfate, sulfite, bisulfite, sulfonate, benzenesulfonate, p-bromophenylsulfonate, chlorobenzenesulfonate, ethanesulfonate, 2-hydroxyethanesulfonate, methanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, p-toluenesulfonate, xylene-sulfonate, tartarate, and the like. A preferred salt is the hydrochloride salt.

The pharmaceutically acceptable acid addition salts are typically formed by reacting a compound of formula I with an equimolar or excess amount of acid. The reactants are generally combined in a mutual solvent such as diethyl ether

or benzene. The salt normally precipitates out of solution within about one hour to 10 days and can be isolated by filtration or the solvent can be stripped off by conventional means.

Bases commonly used for formation of salts include ammonium hydroxide and alkali and alkaline earth metal hydroxides, carbonates, as well as aliphatic and primary, secondary and tertiary amines, aliphatic diamines. Bases especially useful in the preparation of addition salts include ammonium hydroxide, potassium carbonate, methylamine, diethylamine, ethylene diamine and cyclohexylamine.

The pharmaceutically acceptable salts generally have enhanced solubility characteristics compared to the compound from which they are derived, and thus are often more amenable to formulation as liquids or emulsions.

Pharmaceutical formulations can be prepared by procedures known in the art. For example, the compounds can be formulated with common excipients, diluents, or carriers, and formed into tablets, capsules, suspensions, powders, and the like. Examples of excipients, diluents, and carriers that are suitable for such formulations include the following: fillers and extenders such as starch, sugars, mannitol, and silicic derivatives; binding agents such as carboxymethyl cellulose and other cellulose derivatives, alginates, gelatin, and polyvinyl pyrrolidone; moisturizing agents such as glycerol; disintegrating agents such as calcium carbonate and sodium bicarbonate; agents for retarding dissolution such as paraffin; resorption accelerators such as quaternary ammonium compounds; surface active agents such as cetyl alcohol, glycerol monostearate; adsorptive carriers such as kaolin and bentonite; and lubricants such as talc, calcium and magnesium stearate, and solid polyethyl glycols.

The compounds can also be formulated as elixirs or solutions for convenient oral administration or as solutions appropriate for parenteral administration, for instance by intramuscular, subcutaneous or intravenous routes. Additionally, the compounds are well suited to formulation as sustained release dosage forms and the like. The formulations can be so constituted that they release the active ingredient only or preferably in a particular part of the intestinal tract, possibly over a period of time. The coatings, envelopes, and protective matrices may be made, for example, from polymeric substances or waxes.

The particular dosage of a compound of formula I required to modulate NF-kB transcription factor, or any other use disclosed herein, and according to this invention will depend upon the severity of the condition, the route of administration, and related factors that will be decided by the attending physician. Generally, accepted and effective daily doses will be from about 0.1 to about 1000 mg/day, and more typically from about 50 to about 200 mg/day. Such dosages will be administered to a subject in need thereof from once to about three times each day, or more often as needed to effectively modulate NF-kB transcription factor, or any other use disclosed herein.

It is usually preferred to administer a compound of formula I in the form of an acid addition salt, as is customary in the administration of pharmaceuticals bearing a basic group, such as the piperidino ring. It is also advantageous to administer such a compound by the oral route. For such purposes the following oral dosage forms are available.

Formulations

In the formulations which follow, "Active ingredient" means a compound of formula I.

Formulation 1: Gelatin Capsules

Hard gelatin capsules are prepared using the following:

Ingredient	Quantity (mg/capsule)
Active ingredient	0.1 - 1000
Starch, NF	0 - 650
Starch flowable powder	0 - 650
Silicone fluid 350 centistokes	0 - 15

The ingredients are blended, passed through a No. 45 mesh U.S. sieve, and filled into hard gelatin capsules. Examples of specific capsule formulations of raloxifene that have been made include those shown below:

EP 0 747 052 A2

Formulation 2: Raloxifene capsule

Ingredient	Quantity (mg/capsule)
Raloxifene	1
Starch, NF	112
Starch flowable powder	225.3
Silicone fluid 350 centistokes	1.7

Formulation 3: Raloxifene capsule

Ingredient	Quantity (mg/capsule)
Raloxifene	5
Starch, NF	108
Starch flowable powder	225.3
Silicone fluid 350 centistokes	1.7

Formulation 4: Raloxifene capsule

Ingredient	Quantity (mg/capsule)
Raloxifene	10
Starch, NF	103
Starch flowable powder	225.3
Silicone fluid 350 centistokes	1.7

EP 0 747 052 A2

Formulation 5: Raloxifene capsule

Ingredient	Quantity (mg/capsule)
Raloxifene	50
Starch, NF	150
Starch flowable powder	397
Silicone fluid 350 centistokes	3.0

The specific formulations above may be changed in compliance with the reasonable variations provided.
A tablet formulation is prepared using the ingredients below:

Formulation 6: Tablets

Ingredient	Quantity (mg/tablet)
Active ingredient	0.1 - 1000
Cellulose, microcrystalline	0 - 650
Silicon dioxide, fumed	0 - 650
Stearate acid	0 - 15

The components are blended and compressed to form tablets.

Alternatively, tablets each containing 0.1 - 1000 mg of active ingredient are made up as follows:

Formulation 7: Tablets

Ingredient	Quantity (mg/tablet)
Active ingredient	0.1 - 1000
Starch	45
Cellulose, microcrystalline	35
Polyvinylpyrrolidone (as 10% solution in water)	4
Sodium carboxymethyl cellulose	4.5
Magnesium stearate	0.5
Talc	1

The active ingredient, starch, and cellulose are passed through a No. 45 mesh U.S. sieve and mixed thoroughly. The solution of polyvinylpyrrolidone is mixed with the resultant powders which are then passed through a No. 14 mesh U.S. sieve. The granules so produced are dried at 50°-60° C and passed through a No. 18 mesh U.S. sieve. The sodium carboxymethyl starch, magnesium stearate, and talc, previously passed through a No. 60 U.S. sieve, are then added to the granules which, after mixing, are compressed on a tablet machine to yield tablets.

Suspensions each containing 0.1 - 1000 mg of medicament per 5 mL dose are made as follows:

Formulation 8: Suspensions

Ingredient	Quantity (mg/5 ml)
Active ingredient	0.1 - 1000 mg
Sodium carboxymethyl cellulose	50 mg
Syrup	1.25 mg
Benzoic acid solution	0.10 mL
Flavor	q.v.
Color	q.v.
Purified water to	5 mL

The medicament is passed through a No. 45 mesh U.S. sieve and mixed with the sodium carboxymethyl cellulose and syrup to form a smooth paste. The benzoic acid solution, flavor, and color are diluted with some of the water and added, with stirring. Sufficient water is then added to produce the required volume.

Treatment of cells with Compound A*

Human HepG2 cells were cultured in 3:1 v/v mixture of Dulbecco's modified Eagle's medium and Ham's nutrient mixture F12, supplemented with 10 nM selenium, 50 µM 2 amino ethanol, 20 mM HEPES and 50 µg/ml gentamycin and 2.5% fetal bovine serum. When cells reached confluence, the monolayers were rinsed once with HBSS and fed with the above medium without FBS, but with 100 µg/ml fatty-acid free BSA, 0.8 µg/ml oleic acid, and with or without the addition of 10nM compound A. After incubation for 24 hours, cells were processed for nuclear extracts, and nuclear factor assays were performed as described below and by Reifel-Miller et al. (Reifel-Miller, A. E., Berg, D. T. and Grinnell, B. G. (1991) *The Journal of Biological Chemistry* 266, 13873-13882).

Nuclear factor binding by Gel Mobility Retardation Assay

- Nuclear extracts were prepared as described by Dignam, J. D., Lebovitz, R. M. and Roeder, R. G. (1983) *Nucleic Acids Res.* 11, 1475-1489 For the Gel Mobility Retardation Assay the nuclear factor binding site for NF-κB was from VCAM-1 5'-CCTTGAAGGGATTCCCTCCGCT -3 and for BEF-1 was the prototype sequence 5'-AGTGCATGACTGGGCAGCCAGCCAGTGGCAG-3'. The oligonucleotides were labeled at their 5' ends with T4 polynucleotide kinase (Bethesda Research Laboratories, Inc.) and (γ-³²P) ATP (Du Pont-New England Nuclear). Either nuclear extracts containing BEF-1 or the purified human NF-κB proteins (p49 and p50) were incubated with 0.2-0.3 pmol of probe (approximately 10,000 cpm) at 25°C for 30 min. The 10-µl reaction mixture also contained 200 ng of poly (dl-dC) - poly (dl-dC) (Pharmacia), 15% glycerol, 20 mM HEPES (pH 7.9), 100 mM KCl, 5 mM MgCl₂, 0.2 mM EDTA, and 0.5 mM dithiothreitol. Following the 30 minute incubation, samples were subjected to electrophoresis on a 4% low ionic strength polyacrylamide gel as described by Fried, M. and Crothers, D. M. (1981) *Nucleic Acids Res.* 9, 6505-6525. After the gel was dried, the specific protein-DNA complexes were visualized by autoradiography and quantitated using a Betascope 603 Blot Analyzer or phosphorimager (Molecular Dynamics). The results from quantitation with the use of a Betascope 603 Blot Analyzer are expressed as the amount of labeled probe bound/amount of probe free per µg of protein. The data from the phosphorimager was analyzed with TP Label gel software (Ver 1.5, Signal Analytics Corp.) and are expressed as pixel intensity units (PU).

Results

Using the transcription factor binding assays, we assessed the ability of BEF-1 present in cell extracts to bind to the VCAM NF-kB binding site and conversely for purified NF-kB p49 and p50 to bind to the BEF-1 binding site. As shown in Table 1 using two levels of BEF-1 containing nuclear extract, we obtained a concentration-dependent binding of BEF-1 to the VCAM-1 NF-kB binding site. As shown in Table 2, purified NF-kB proteins (p50 and p49: Promega) bound to the prototype BEF-1 binding site in a concentration-dependent manner. As would be expected these two NF-kB proteins also bound to the VCAM NF-kB binding site.

The effect of compound A on the level of intracellular BEF-1 was determined by measuring the BEF-1 binding activity in nuclear extracts prepared from compound A -treated and untreated human HepG2 cells. As shown in Table 3, in four separate experiments the treatment of cells with 10 nM compound A resulted in a 193 to 293% (mean of 253 +/- 42) increase in the level BEF-1. Thus, compound A increases the levels of the intracellular repressor BEF-1, and thus can modulate the activity of genes controlled by BEF-1. Further, the ability of BEF-1 to interact at NF-kB binding sites, indicates that compound A could be effective in blocking the action of the important cellular regulatory molecule NF-kB.

Table 1

Binding of BEF-1 to an NF-kB binding site		
BEF-1 containing Nuclear Extract	Binding Site	BEF-1/Binding Site Complex (PIU)
None.	VCAM1(NF-kB)	0
1.4ug	VCAM1(NF-kB)	8.63
2.8ug	VCAM1(NF-kB)	15.03

Table 2

Binding of purified NF-kB to the BEF-1 and NF-kB binding sites.		
NF-kB proteins	Binding Site	NF-kB/Binding Site Complex (PIU)
None.	BEF-1	0.88
p50 56pg	BEF-1	4.46
p50 112pg	BEF-1	11.16
p49 74pg	BEF-1	42.66
p49 148pg	BEF-1	77.73
None	VCAM1(NF-kB)	-0.04
P50 112pg	VCAM1(NF-kB)	46.19
P49 148pg	VCAM1(NF-kB)	17.02


Table 3

The effect of compound A on the level of intra-cellular BEF-1			
Experiment Number	Compound A Treatment	Binding Activity (bound/free per ug)	Percent Change with Treatment
1	-	0.12	
	+	0.33	292
2	-	0.14	
	+	0.27	195
3	-	0.12	
	+	0.33	275
4	-	0.12	
	+	0.30	250

*Compound A is of the formula I wherein R₁ and R₃ are hydroxy, and R₂ is pyrrolidino.


Claims

1. The use of a compound having the formula



(I)

wherein R¹ and R³ are independently hydrogen, -CH₃,




wherein Ar is optionally substituted phenyl;

R² is selected from the group consisting of pyrrolidine, hexamethylenemino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof, in the preparation of a medicament useful for modulating NF- κ B transcription factor.

2. The use of Claim 1 wherein said compound is the hydrochloride salt thereof.

3. The use of Claim 1 wherein said compound is



or its hydrochloride salt.

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 747 052 A3

(12)

EUROPEAN PATENT APPLICATION

(88) Date of publication A3:
26.02.1997 Bulletin 1997/09

(51) Int. Cl.⁶: A61K 31/445, A61K 31/40,
A61K 31/55

(43) Date of publication A2:
11.12.1996 Bulletin 1996/50

(21) Application number: 96303877.3

(22) Date of filing: 30.05.1996

(84) Designated Contracting States:
AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL
PT SE
Designated Extension States:
AL LT LV SI

(30) Priority: 07.06.1995 US 474936

(71) Applicant: ELI LILLY AND COMPANY
Indianapolis, Indiana 46285 (US)


(72) Inventors:

- Berg, David Thompson
Beech Grove, Indiana 46107 (US)
- Calnek, David Scott
Indianapolis, Indiana 46250 (US)
- Grinnell, Brian William
Indianapolis, Indiana 46220 (US)


(74) Representative: Hudson, Christopher Mark et al
Lilly Industries Limited
European Patent Operations
Erl Wood Manor
Windlesham Surrey GU20 6PH (GB)

(54) Methods of modulating NF-KB transcription factor

(57) A method of modulating NF-kB transcription factor comprising administering to a human in need thereof an effective amount of a compound having the formula



wherein R¹ and R³ are independently hydrogen, -CH₃,



wherein Ar is optionally substituted phenyl;

EP 0 747 052 A3

EP 0 747 052 A3

R² is selected from the group consisting of pyrrolidine, hexamethylenearmino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 96 30 3877

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
P,X	EP 0 664 121 A (LILLY CO ELI) 26 July 1995 * claim 3 *	1-3	A61K31/445 A61K31/40 A61K31/55
P,X	EP 0 659 427 A (LILLY CO ELI) 28 June 1995 * page 7 - page 8 *	1-3	
P,X	WO 96 12491 A (LILLY CO ELI) 2 May 1996 * claim 6 *	1-3	
P,X	EP 0 664 126 A (LILLY CO ELI) 26 July 1995 * page 6, line 28 - line 48 *	1-3	
P,X	EP 0 668 075 A (LILLY CO ELI) 23 August 1995 * page 8 *	1-3	
A	DATABASE EMBASE ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL Dialog Acc.No: 9449082, 1994 A.S. LEVENSON ET AL.: "Transfection of human estrogen receptor (ER) cDNA into ER-negative mammalian cell lines" XP002019417 * abstract * & J. STEROID BIOCHEM. MOL. BIOL., vol. 51, no. 5-6, 1994, pages 229-239,	1-3	TECHNICAL FIELDS SEARCHED (Int.Cl.6) A61K
A	JOURNAL OF BONE AND MINERAL RESEARCH, vol. 8, no. s1, August 1993, page s118 XP002019416 N. YANG ET AL.: "Raloxifene, an antiestrogen, stimulates the effects of estrogen on inhibiting bone resorption through regulating TGF-beta-3 expression in bone" * abstract *	1-3	
		-/-	
The present search report has been drawn up for all claims			
Place of search MUNICH		Date of completion of the search 25 November 1996	Examiner Foerster, W
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

EPO FORM 150 (03.92) (P0403)



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 96 30 3877

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
T	DATABASE EMBASE ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL Dialog Acc. No: 10000389, 1996 R. GALIEN ET AL.: "Involvement of CCAAT/enhancer-binding protein and nuclear factor kappaB binding sites in interleukin-6 promoter inhibition by estrogens" XP002019418 * abstract * & MOLECULAR ENDOCRINOLOGY, vol. 10, no. 6, June 1996, pages 713-722,	1	
D,A	--- US 4 418 068 A (JONES CHARLES D) 29 November 1983 * column 2, line 15 - line 40; claims 42,48 * -----	1-3	
			TECHNICAL FIELDS SEARCHED (Int.Cl.6)
The present search report has been drawn up for all claims			
Place of search MUNICH		Date of completion of the search 25 November 1996	Examiner Foerster, W
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

EPO FORM 1503 03.92 (P04C01)